Company History

2010

• Evotec is adding a core capability in metabolic disease biology by aquiring DeveloGen
• Start of Phase II with EVT 101 (Treatment-Resistant Depression)
• Integrated Drug Discovery Alliance with Genentech
• Successful completion of first-in-man study with EVT 103
• Extension of CHDI collaboration (Huntington's Disease)

2009

• TecDAX re-entry / Evotec voluntarily delist from NASDAQ
• Evotec and Boehringer Ingelheim extend and broaden research collaboration
• Start Phase I with EVT 103 (Treatment-Resistant Depression)
• Evotec Accelerates Growth Strategy of its Discovery Alliance Business with Acquisition of Indian RSIPL
• Successful Completion of first Phase I Study with EVT 401 (P2X7)
• Evotec Acquires Zebrafish Screening Operations of Summit Corporation
• Evotec and Roche to develop EVT 101 for Treatment-Resistant Depression
• Evotec 2012 Action Plan to Focus and Growth
• Unsuccessful partnering of EVT 201 and failed Phase II of EVT 302 in smoking cessation results in the decision to only pursue proprietary assets if funded

2008

• Evotec Completes Acquisition of Renovis, Nasdaq-Listing
• Start Phase I with P2X7 Antagonist (Rheumatoid arthritis)
• Evotec Participates in the Sale of Direvo Biotech to Bayer Healthcare
• Three-Year Drug Discovery Collaboration with Novartis
• 3 additional milestone payments from Boehringer Ingelheim
• Fragment based drug discovery agreement with Ono

2007

• Evotec and Research Support International Limited form Evotec-RSIL Ltd, a Joint Venture in India for the Design, Synthesis, Management and Commercialisation of Compound Libraries
• Foundation of European ScreeningPort GmbH with the support of Evotec
• Evotec Sells its Chemical Development Business to Aptuit
• New multiyear collaboration with Boehringer Ingelheim with focus on Alzheimer`s disease

2006

• In-licenses from Roche two Phase I MAO-B inhibitors
• Raises EUR 18.5 million in a capital increase
• Completes clinical Phase I for EVT 101
• Evotec AG sells Evotec Technologies to PerkinElmer
• Further expansion and extension of Boehringer Ingelheim drug discovery collaboration
• Second milestone payment from Boehringer Ingelheim
• Extension of global medicinal chemistry agreement and medicinal chemistry collaboration in oncology with Roche
• Forming a global alliance with Roche to jointly discover and develop compounds in the area of CNS

2005

• In-licensing from Roche Phase I EVT 201 (Insomnia)
• Capital increase,  EUR 28.4 million
• Start Phase I with EVT 101
• First milestone payment from Boehringer Ingelheim
• Extension of Boehringer Ingelheim collaboration
• Extension of medicinal chemistry agreement with Roche

2004

• Evotec Neurosciences in-licenses from Roche drug candidates for the treatment of various CNS disorders
• Three-year collaboration with Boehringer Ingelheim with an initial focus on CNS-diseases
• Strategic global medicinal chemistry agreement with Roche

2003

• Expansion of Roche collaboration into the area of lead optimisation in oncology
• Evotec Neurosciences and Takeda enter into a four-year collaboration to identify novel Alzheimer's disease targets

2002

• Spinning off its technology development business into its subsidiary Evotec Technologies
• Extension of Discovery Chemistry Agreement with Roche

2001

• Initial cooperation with Roche with focus on chemical compound libraries

2000

• Merge with Oxford Asymmetry International plc,  form Evotec OAI AG, to become the leader in the discovery and development of novel small molecule drugs
• Successful market introduction of EVOscreen®

1999

• Establishes Evotec Neurosciences GmbH in Hamburg
• In November Evotec BioSystems AG goes public

1998

• Raising DM 46 million (EUR 23.5 million), the largest private placements seen in the European biotech sector

1996

• Collaborations with Novartis and SmithKlineBeecham to develop EVOscreen®  (High-Throughput Screening System)

1993

• Evotec BioSystems GmbH was founded in Hamburg, Germany. Among the founders were Nobel Laureate Professor Manfred Eigen, Dr Karsten Henco, Dr Ulrich Aldag, Dr Freimut Leidenberger, Dr Heinrich Schulte, Professor Rudolf Rigler and Dr Charles Weissmann